

Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over

Information for the public

Published: 29 May 2024

www.nice.org.uk

Dabrafenib (Finlee) with trametinib (Spexotras) is available on the NHS as a possible treatment for:

- low-grade glioma with a BRAF V600E mutation in children and young people 1 year and over who need systemic treatment (treatment that works throughout the whole body, such as medicine taken by mouth like dabrafenib with trametinib)
- high-grade glioma with a BRAF V600E mutation in children and young people 1 year and over after at least 1 radiation or chemotherapy treatment.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on brain tumours](#) may be a good place to find out more.

These organisations can give you advice and support:

- [The Brain Tumour Charity](#), 0808 800 0004
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6139-9